Neurosterix's funding is intended to support planned Phase 2 testing and other drug programs, and Addex's stake is valued at $18.6 million. Addex received no cash from the round, but the funding and stated stake value make this favorable for Addex.
The outside funding gives Neurosterix resources for planned Phase 2 testing of its schizophrenia drug and work on other drug programs. That may strengthen the value of Addex's stake. Addex did not put money into the round, so it receives no direct cash from it.
Follow Addex Therapeutics (ADXN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ADXN